KAICO is a bio-startup from Kyushu University, established in April 2018 with the aim of developing pharmaceuticals, diagnostics, and reagents for difficult-to-express proteins.
KAICO’s core technology is supported by tiny silkworms. By injecting artificial “baculoviruses” into silkworms, recombinant proteins are expressed efficiently, which are then collected and purified to obtain various target proteins.
Utilizing this technology, we have so far developed an antibody assay kit for COVID-19 and an “edible vaccine (oral vaccine)” for animals.
On this page, KAICO members share their milestone story, and how it shapes KAICO.
Challenge to develop “edible vaccines”! How a businessperson with a background in humanities establish a bio-startup?